Project Grant R01EY038853
- Federal Grant Award Summary The University of Pittsburgh received a $243,542 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), awarded September 15, 2025, with a completion date of August 31, 2027. This research project investigates the neural mechanisms underlying visual continuity during eye blinks—a fundamental capability that allows primates to maintain stable visual perception despite frequent retinal disruptions from rapid eye movements...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $2.08M Project Grant under the Vision Research program (CFDA 93.867) to the University of Pittsburgh from September 30, 2025, through September 29, 2027. The project investigates sensorimotor processing in the oculomotor system, specifically addressing how the brain intercepts moving targets through interceptive saccades (rapid eye movements). The research addresses a critical gap in knowledge regarding the sensory and...
- Federal Grant Award Summary The National Eye Institute awarded The Aird a $610,000 Project Grant under the Vision Research program (CFDA 93.867) beginning September 1, 2025, with completion targeted for August 31, 2026. The primary deliverable is the development and validation of a novel Adaptive Optics Optical Coherence Tomography (AO-OCT) system designed for high-resolution, wide-field retinal imaging in rodent models, specifically mice. The system will integrate adaptive optics technology...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $571,206 Project Grant to the University of Maryland, Baltimore effective May 1, 2026, through March 31, 2030, under the Vision Research program (CFDA 93.867). This award funds the development, refinement, and validation of adaptive optics-optical coherence tomography (AO-OCT) biomarkers for glaucoma detection and progression monitoring. The project will deliver research products including validated imaging biomarkers capable...
- Federal Grant Award Summary The National Eye Institute (NEI) Vision Research program (CFDA 93.867) awarded $722,904 to the University of California, Los Angeles on May 1, 2026, for the "Researching OCT Biomarkers in Uveitis Clinical Trials (ROBUST)" project, extending through April 30, 2031. This project will deliver a secondary analysis of optical coherence tomography (OCT) imaging and clinical datasets from four NEI-funded uveitis randomized clinical trials. The research will...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $421,136 Project Grant to the University of Maryland, College Park, effective August 1, 2025, through July 31, 2027, under the Vision Research program (CFDA 93.867). This award supports research into advanced wavefront shaping techniques designed to enable high-resolution fundus imaging in patients with ocular opacities—conditions affecting the cornea and lens that currently prevent effective posterior segment eye...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded the University of Rochester a $1.31 million Project Grant under the Vision Research program (CFDA 93.867) effective July 1, 2025, through April 30, 2029, to investigate the pathogenic role of secretory phospholipase A2-IIA (PLA2G2A/sPLA2-IIA) in age-related macular degeneration (AMD). AMD is a leading cause of adult blindness with limited treatment options, presenting in two forms: geographic atrophy (dry form) and choroidal...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded The Washington University $427,625 through the Vision Research program (CFDA 93.867) for a two-year project (April 1, 2026–March 31, 2028) to develop novel statistical methodologies for detecting visual field progression in primary open-angle glaucoma (POAG). The project leverages data from the Ocular Hypertension Treatment Study (OHTS) to create three primary deliverables: (1) a change-point statistical model for mean...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded a $638,625 Project Grant to the University of California, San Diego, effective August 1, 2025 through July 31, 2028, under the Vision Research program (CFDA 93.867). The award funds research to investigate the mechanisms of drusen formation in age-related macular degeneration (AMD), a leading cause of blindness affecting approximately 196 million people globally. The research employs a novel quartz crystal microbalance assay...
- Federal Project Grant Award Summary The University of Miami's Office of Research Administration - School of Medicine received a $628,100 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), effective May 1, 2026, through April 30, 2030. The award funds research focused on characterizing lens remodeling mechanisms in childhood myopia development. The project will develop and deploy novel measurement technologies to quantify three-dimensional lens...
The University of Pittsburgh received a $679,650 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867), awarded June 1, 2026, with completion scheduled for May 31, 2030. This research project delivers advanced diagnostic and imaging capabilities for understanding immune responses in uveitis, an inflammatory eye condition responsible for up to 10% of blindness in the United States. The primary deliverable is the development and validation of Adaptive Optics Ophthalmoscopy (AOO)—a non-invasive, label-free imaging technology that enables real-time assessment of immune cell morphology and dynamics within the living eye. This technology represents a significant advancement over current diagnostic approaches that rely on systemic assessments rather than direct ocular measurements. The research will produce quantitative immunological characterizations and validated biomarkers by establishing baseline immunological differences between infectious and non-infectious uveitis forms through conventional assays including flow cytometry and cytokine analysis (Aim 1), then demonstrating AOO's capability to detect morphological and dynamic changes associated with immune cells and potentially certain pathogens in posterior uveitis (Aim 2). The expected outcomes include rigorous new clinical biomarkers for evaluating treatment efficacy in both clinical settings and clinical trials, potentially revolutionizing the diagnostic toolkit for posterior uveitis and addressing a critical gap in real-time immune response assessment in human eyes.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $679.7k | 6/5/26 |